Mycobacterium avium subsp. paratuberculosis antigens (AhpC, Gsd, p12, mpa) (MAP antigens (AhpC, Gsd, p12, mpa))

The target Mycobacterium avium subsp. paratuberculosis antigens AhpC, Gsd, p12, mpa refers to a specific set of four proteins derived from the MAP bacterium, which is the causative agent of Johne's disease in animals and is implicated in human Crohn's disease [1.3.2, 1.4.3]. These antigens include Alkyl hydroperoxide reductase C (AhpC), Glycosyl transferase d (Gsd), Protein 12 (p12), and Mycobacterial proteasome ATPase (Mpa) [1.3.2, 1.5.3]. In therapeutic development, these four antigens are typically combined into a single fusion protein, often referred to as the HAV (Human Avium Vaccine) construct [1.3.2, 1.4.1]. This construct is delivered via viral vectors, such as ChAdOx2 or Modified Vaccinia Ankara (MVA), to stimulate a robust Th1-polarized T-cell response against MAP-infected cells [1.3.1, 1.3.3]. The primary goal of targeting these antigens is to eliminate the underlying MAP infection, which is hypothesized to drive chronic intestinal inflammation in a subset of Crohn's disease patients [1.4.2, 1.5.3]. Clinical trials have demonstrated that vaccines targeting this antigen complex are safe, well-tolerated, and capable of inducing significant cellular immunity [1.3.3]. Beyond Crohn's disease, these antigens are also being investigated for their potential roles in other inflammatory conditions, such as multiple sclerosis and type 1 diabetes, where MAP exposure has been implicated [1.1.4, 1.5.2].

Other names

HAV antigensHuman Avium Vaccine antigensMAP fusion protein antigensChAdOx2-HAV antigensMVA-HAV antigensMAP1589c, MAP1234, MAP2444c, MAP1235

Induction of antigen-specific T-cell mediated immune response